AtaiBeckley Inc 2026 Outlook: Shares Drop, Valuation Highlights Mental‑Health Focus
AtaiBeckley Inc. shares fall to $3.75 as the Nasdaq‑listed mental‑health biotech, linked to Berlin’s ATAI Life Sciences, projects 2026 growth amid a P/E of –4.88, a 5.98 P/B and a $1.36 bn market cap.
2 minutes to read
